[“Candida Auris: Ignore it and Other Emerging Pathogens at Your Own Risk!” Registration for this event is FREE at: https://bit.ly/42lO4fG](https://wbbsec.com/press-releases/wbb-securities-will-be-sponsoring-a-demy-colton-virtual-salon-webinar-on-may-17-2023/)
[“Candida Auris: Ignore it and Other Emerging Pathogens at Your Own Risk!” Registration for this event is FREE at: https://bit.ly/42lO4fG](https://wbbsec.com/press-releases/wbb-securities-will-be-sponsoring-a-demy-colton-virtual-salon-webinar-on-may-17-2023/)
powered by bulletin

With Big Pharma In Retreat, Ackman And Novartis Try A New Blueprint For Drug Companies

By:Posted: Apr 22nd, 2014In: Opinions & Features

4.22.2014 | Forbes

By Steve Brozak

Yesterday in a move that returned attention to healthcare takeovers, Bill Ackman, CEO of the hedge fund Pershing Square Capital, announced a bold and unusual move by partnering with pharmaceutical company, Valeant Pharmaceuticals International, Inc. to acquire a major stake in another biotech.  In this case it is Allergan, Inc., the makers of the injectable wrinkle-remover BOTOX, and several ophthalmic treatments.

For the full article, please click here.

Recent Posts